Literature DB >> 8797137

Impairment of coronary blood flow regulation by endothelium-derived nitric oxide in dogs with alloxan-induced diabetes.

T Matsunaga1, K Okumura, H Ishizaka, R Tsunoda, S Tayama, T Tabuchi, H Yasue.   

Abstract

Diabetes mellitus is a major cause of ischemic coronary artery disease. Endothelial dysfunction is implicated in the pathogenesis of diabetic vascular disease. To examine coronary blood flow (CBF) regulation with endothelium-derived nitric oxide (EDNO) in the diabetic state, we compared the effects of both acetylcholine (ACh) and adenosine (Ado) on left circumflex coronary artery (LCX) blood flow in 12 vehicle-treated and 21 dogs made diabetic with alloxan anesthetized with pentobarbital. All dogs were pretreated with aspirin to inhibit endogenous prostaglandins. None of the hemodynamic parameters were significantly different in the two groups. The percent change in coronary vascular resistance (CVR) after ACh (100 ng/kg) infusion was significantly attenuated in diabetic dogs (-56.5 +/- 1.4%) as compared with vehicle-treated dogs (-64.5 +/- 1.2%) (p < 0.01), whereas the effect of Ado (1 microgram/kg) was not different between the two groups (-71.1 +/- 1.5% in vehicle, -67.0 +/- 1.3% in diabetes). After infusion of incremental doses of NG-nitro-L-arginine methyl ester (L-NAME) 10(-5)-10(-3)M, the effect of ACh was progressively inhibited in both groups and was different no longer between the two groups after the maximal dose. L-Arginine (L-ARG), but not D-ARG, significantly restored the effect of ACh in diabetic dogs but did not affect vehicle-treated dogs. The effect of Ado did not change after L- and D-ARG administration. Cu, Zn-superoxide dismutase (Cu, Zn-SOD) had no effect on any of the effects of ACh and Ado in diabetic dogs. Regulation of CBF with EDNO is impaired in dogs with alloxan-induced diabetes, and this impairment is partially restored by L-ARG.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797137     DOI: 10.1097/00005344-199607000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.

Authors:  X L Du; D Edelstein; S Dimmeler; Q Ju; C Sui; M Brownlee
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Vascular dysfunction in retinopathy-an emerging role for arginase.

Authors:  Ruth B Caldwell; Wenbo Zhang; Maritza J Romero; R William Caldwell
Journal:  Brain Res Bull       Date:  2009-09-06       Impact factor: 4.077

Review 3.  Endothelial dysfunction in diabetes.

Authors:  A S De Vriese; T J Verbeuren; J Van de Voorde; N H Lameire; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction.

Authors:  K Terata; L J Coppey; E P Davidson; J A Dunlap; D D Gutterman; M A Yorek
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Progressive Decrease in Coronary Vascular Function Associated With Type 2 Diabetic Heart Disease.

Authors:  Rajesh Katare; James T Pearson; Jason Kar-Sheng Lew; Melanie Wei; Hirotsugu Tsuchimouchi; Cheng-Kun Du; Dong-Yun Zhan; Keiji Umetani; Mikiyasu Shirai; Daryl O Schwenke
Journal:  Front Physiol       Date:  2018-06-06       Impact factor: 4.566

6.  Vascular Dysfunction in Horses with Endocrinopathic Laminitis.

Authors:  Ruth A Morgan; John A Keen; Brian R Walker; Patrick W F Hadoke
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.